https://www.selleckchem.com/products/ipi-549.html
In this pilot clinical study, we report the beneficial effects of beta glucans derived from two strains AFO-202 and N-163 of a black yeast Aureobasidium pullulans on the biomarkers for cytokine storm and coagulopathy in COVID-19 patients. A total of 24 RT-PCR positive COVID-19 patients were recruited and randomly divided into three groups (Gr) Gr. 1 control (n=8) - Standard treatment; Gr. 2 Standard treatment +AFO-202 beta glucan (n=8); and Gr. 3, Standard treatment +combination of AFO-202 and N-163 beta glucans (n=8) for 30 days. There
Like
Comment
Share
